Assessing real-world representativeness of prospective registry cohorts in oncology: insights from patients with esophagogastric cancer
- PMID: 37871837
- DOI: 10.1016/j.jclinepi.2023.10.009
Assessing real-world representativeness of prospective registry cohorts in oncology: insights from patients with esophagogastric cancer
Abstract
Objectives: This study aimed to explore the real-world representativeness of a prospective registry cohort with active accrual in oncology, applying a representativeness metric that is novel to health care.
Study design and setting: We used data from the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP) registry and from the population-based Netherlands Cancer Registry (NCR). We used Representativeness-indicators (R-indicators) and overall survival to investigate the degree to which the POCOP cohort and clinically relevant subgroups were a representative sample compared to the NCR database. Calibration using inverse propensity score weighting was applied to correct differences between POCOP and NCR.
Results: The R-indicator of the entire POCOP registry was 0.72 95% confidence interval [0.71, 0.73]. Representativeness of palliative patients was higher than that of potentially curable patients (R-indicator 0.88 [0.85, 0.90] and 0.70 [0.68, 0.71], respectively). Stratification to clinically relevant subgroups based on treatment resulted in higher R-indicators of the respective subgroups. Both after stratification and calibration weighting survival estimates in the POCOP registry were more similar to that in the NCR population.
Conclusion: This study demonstrated the assessment of real-world representativeness of patients who participated in a prospective registry cohort and showed that real-world representativeness improved when the variability in treatment was accounted for.
Keywords: Esophageal cancer; Gastric cancer; Health-related quality of life; R-indicators; Representativeness; Survival.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest MS has served as a consultant for BMS and Lilly. NHM has served as a consultant for BMS, Merck, Lilly, Astra Zeneca and Servier. RV reports grants from BMS and has served as a consultant for Daiichi Sankyo. HvL has served as a consultant for BMS, Dragonfly, Lilly, Merck, Nordic Pharma and Servier and has received research funding and/or medication supply from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Nordic, Philips, Roche and Servier. SCK, JB, TK, CJvdZ, EAK, LvB, and BRK have no disclosures.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical